The Patent Finder
AU

Astellas US LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

17 patents currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2034. from the record

Of the 15 now held by other companies, 7 name Jiangsu Aosaikang Pharmaceutical Co. Ltd. as their current owner, and 8 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2034
Next term end
12
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Aryl Alkynamide Derivatives (US 11,912,679) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Abiraterone Prodrugs (US 11,957,696) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 17, 2026

What they patent

The 5 largest of its 12 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,273,171Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
In forceHigh confidence
US 11,491,176Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
In forceHigh confidence
US 12,016,875Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
In forceHigh confidence
US 10,874,641Methods of Treating Acute Kidney Injury
In force
 · High confidence
In forceHigh confidence
US 11,034,670Poly-Adp Ribose Polymerase (PARP) Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,993,585Poly-Adp Ribose Polymerase (PARP) Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 11,596,667A Method for Treating or Preventing Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
In force
 · High confidence
In forceHigh confidence
US 12,600,986Nucleic Acid Molecules Containing Spacers and Methods of Use Thereof
In force
 · Low confidence
In forceLow confidence
US 10,792,292Abiraterone Prodrugs
In force
 · High confidence
In forceHigh confidence
US 11,559,534Abiraterone Prodrugs
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 15 patents in force now held by others · 14 patents ended · 25 applications pending · 17 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited